BRCA1 and cancer: Since cancers with defective homology directed double-strand break repair due to BRCA1 or BRCA2 mutations are particularly sensitive to platinum therapy and PARP inhibitors, it is conceivable that this subset of gastric cancers might also benefit from their usage.